NCT00373711

Brief Summary

The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt.

Trial Health

10
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 6, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 8, 2006

Completed
8 months until next milestone

Study Start

First participant enrolled

May 1, 2007

Completed
Last Updated

June 21, 2022

Status Verified

April 1, 2011

First QC Date

September 6, 2006

Last Update Submit

June 16, 2022

Conditions

Thyroid Cancer

Interventions

Iodine-124DRUG

2 mCi, oral

Also known as: Eastern Isotopes
Iodine-123DRUG

2 mCi, oral

Also known as: MDS Nordion
F-18 FDGDRUG

10-15 mCi, iv

Also known as: Fludeoxyglucose (18 F), fluorodeoxyglucose (18 F), MIPS

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Participants with Thyroid cancer

You may qualify if:

  • Treated thyroid cancer.
  • Detectable levels of Tg.
  • Referred for I-123 WBS and F-18 FDG PET/CT for detection of recurrent thyroid cancer.
  • Able to have a I-124 PET/CT the day after I-123 WBS and F-18 FDG PET/CT
  • Patients older than 18-year-old.
  • Patients with history of treated thyroid cancer and suspected recurrent thyroid cancer based on detectable levels of Tg.
  • Patients must have I-123 WBS and F-18 FDG PET/CT performed prior to the I-124 PET/CT.

You may not qualify if:

  • Patients who cannot complete I-123 WBS and F-18 FDG PET/CT.
  • Pregnant women.
  • Healthy volunteers.
  • Patients participating in other research studies.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Thyroid Neoplasms

Interventions

Iodine-124Iodine-123Fluorodeoxyglucose F18

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck NeoplasmsEndocrine System DiseasesThyroid Diseases

Intervention Hierarchy (Ancestors)

DeoxyglucoseDeoxy SugarsCarbohydrates

Study Officials

  • Andrei Iagaru

    Stanford University

    PRINCIPAL INVESTIGATOR

  • Iain Ross McDougall

    Stanford University

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 6, 2006

First Posted

September 8, 2006

Study Start

May 1, 2007

Last Updated

June 21, 2022

Record last verified: 2011-04